Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cancergen.2012.05.012 http://scihub22266oqcxt.onion/10.1016/j.cancergen.2012.05.012 22868000/?report=reader!3784316!22868000     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Genet 2012 ; 205 (7-8): 391-404 Nephropedia Template TP {{tp|p=22868000|t=2012. Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma |pdf=|usr=}}{{22868000}} gab.com Text Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma JO: Cancer Genet http://www.kidney.de/pget.php?&tw=1&pmid=22868000 #FOAvip Ewing sarcoma (ES) is the second most common bone tumor in children and young adults, with dismal outcomes for metastatic and relapsed disease. To better understand the molecular pathogenesis of ES and to identify new prognostic markers, we used molecular inversion probes (MIPs) to evaluate copy number alterations (CNAs) and loss of heterozygosity (LOH) in formalin-fixed paraffin-embedded (FFPE) samples, which included 40 ES primary tumors and 12 ES metastatic lesions. CNAs were correlated with clinical features and outcome, and validated by immunohistochemistry (IHC). We identified previously reported CNAs, in addition to SMARCB1 (INI1/SNF5) homozygous loss and copy neutral LOH. IHC confirmed SMARCB1 protein loss in 7-10% of clinically diagnosed ES tumors in three separate cohorts (University of Utah [N = 40], Children's Oncology Group [N = 31], and University of Michigan [N = 55]). A multifactor copy number (MCN)-index was highly predictive of overall survival (39% vs. 100%, P < 0.001). We also identified RELN gene deletions unique to 25% of ES metastatic samples. In summary, we identified both known and novel CNAs using MIP technology for the first time in FFPE samples from patients with ES. CNAs detected by microarray correlate with outcome and may be useful for risk stratification in future clinical trials. Twit Text FOAVip Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma ????Cancer Genet http://www.kidney.de/pget.php?&tw=1&pmid=22868000 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22868000 #FOAvip English Wikipedia <ref>{{Cite pmid|22868000}}</ref> Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma #MMPMID22868000 Jahromi MS; Putnam AR; Druzgal C; Wright J; Spraker-Perlman H; Kinsey M; Zhou H; Boucher KM; Randall RL; Jones KB; Lucas D; Rosenberg A; Thomas D; Lessnick SL; Schiffman JD Cancer Genet 2012[Jul]; 205 (7-8): 391-404 PMID22868000show ga Ewing sarcoma (ES) is the second most common bone tumor in children and young adults, with dismal outcomes for metastatic and relapsed disease. To better understand the molecular pathogenesis of ES and to identify new prognostic markers, we used molecular inversion probes (MIPs) to evaluate copy number alterations (CNAs) and loss of heterozygosity (LOH) in formalin-fixed paraffin-embedded (FFPE) samples, which included 40 ES primary tumors and 12 ES metastatic lesions. CNAs were correlated with clinical features and outcome, and validated by immunohistochemistry (IHC). We identified previously reported CNAs, in addition to SMARCB1 (INI1/SNF5) homozygous loss and copy neutral LOH. IHC confirmed SMARCB1 protein loss in 7-10% of clinically diagnosed ES tumors in three separate cohorts (University of Utah [N = 40], Children's Oncology Group [N = 31], and University of Michigan [N = 55]). A multifactor copy number (MCN)-index was highly predictive of overall survival (39% vs. 100%, P < 0.001). We also identified RELN gene deletions unique to 25% of ES metastatic samples. In summary, we identified both known and novel CNAs using MIP technology for the first time in FFPE samples from patients with ES. CNAs detected by microarray correlate with outcome and may be useful for risk stratification in future clinical trials. |*Gene Dosage[MESH] |*Molecular Probes[MESH] |Adolescent[MESH] |Adult[MESH] |Bone Neoplasms/*genetics/pathology[MESH] |Cell Adhesion Molecules, Neuronal/genetics[MESH] |Child[MESH] |Child, Preschool[MESH] |Chromosomal Proteins, Non-Histone/genetics[MESH] |DNA-Binding Proteins/genetics[MESH] |Extracellular Matrix Proteins/genetics[MESH] |Female[MESH] |Gene Deletion[MESH] |Humans[MESH] |Immunohistochemistry[MESH] |Infant[MESH] |Loss of Heterozygosity[MESH] |Male[MESH] |Nerve Tissue Proteins/genetics[MESH] |Paraffin Embedding[MESH] |Reelin Protein[MESH] |SMARCB1 Protein[MESH] |Sarcoma, Ewing/*genetics/pathology[MESH] |Serine Endopeptidases/genetics[MESH] |Transcription Factors/genetics[MESH]Molecular inversion probe analysis detects novel copy number alteratio(epmc).pdf DeepDyve Pubget Overpricing